Imvax locks in $112m Series C
Philadelphia-based Imvax, a biotechnology company, has closed $112 million in Series C financing.
Philadelphia-based Imvax, a biotechnology company, has closed $112 million in Series C financing.
Copyright PEI Media
Not for publication, email or dissemination